An expert participating in the ongoing clinical trials reviewing Celltrion’s Covid-19 monoclonal antibody therapy Regkirona said the antibody treatment would play a key role in overcoming the pandemic.
“Vaccine will train the immune system to fight against infections, while antibody therapy can immediately treat Covid-19, and using both medications will complement each other to ensure that the majority of the population is protected from the potentially severe effects of the pandemic,” said Professor Adrian Streinu-Cercel of Infectious Diseases at the Carol Davila University of Medicine and Pharmacy in Romania in charge of global trials conducted in the country,
According to Celltrion, Streinu-Cercel said monoclonal antibodies have merits compared to other types of Covid-19 treatments. Antibody therapies are designed to target specific parts of the virus, resulting in a lowered risk of side effects.
The Romanian expert added that antibody treatments have proven their safety and efficacy as health providers have long been prescribing the drugs. He stressed that pharmaceutical companies would have to continue their research for Covid-19 treatments because nations and particular age groups have difficulties receiving vaccines despite the increasing vaccine rollouts.
Dr. Streinu-Cercel’s presentation has drawn attention in line with the recently disclosed topline results of the global phase 3 clinical trial of Regkirona.
Last week, the Korean company said that giving Regkirona to Covid-19 patients in early stages could reduce the progression rate to severe symptoms in mild-to-moderate patients. The company conducted studies on 1,315 Covid-19 patients with mild-to-moderate symptoms in 13 countries, including South Korea, the U.S., Spain, and Romania. It also confirmed that patients recovered faster when administered Regkirona compared to the placebo group.
“Dr. Streinu-Cercel said that the Covid-19 antibody treatment eases the burden of healthcare providers’ battle against the pandemic by lowering the progression rate to severe cases, which could lead to hospitalization for oxygen therapy and even resulting in death, and also play a key role in preventing Covid-19 infections,” Celltrion Healthcare Official said.
Regkirona, an antibody treatment that has shown significant results in the global phase 3 clinical trials, will play that role, and Celltrion expects the positive outcome to continue as it has been negotiating with many nations for its exports.”